Industry Rating - The report maintains an "Outperform" rating for the scientific instruments industry, consistent with the previous rating [1]. Core Insights - The scientific instruments market in China surpassed 220 billion yuan in 2023, with a growth rate exceeding 12%. The market is dominated by high-end foreign brands, and there is a significant push for domestic alternatives driven by government policies [2][12]. - The domestic market for mass spectrometers reached 16.712 billion yuan in 2023, with foreign companies holding over 90% of the global market share. The import rate for mass spectrometers has decreased from 89% in 2018 to 81% in 2023, indicating a gradual shift towards domestic production [3][41]. - The electronic measurement instruments market is projected to exceed 40 billion yuan in 2024, with a notable focus on mid-to-high-end products. The market for oscilloscopes is expected to reach 650 million USD by 2025 [4]. Summary by Sections 1. Scientific Instruments Industry - The scientific instruments industry is characterized by high-end foreign brands dominating the market, while domestic brands struggle to gain market share. The government has introduced various policies to promote domestic innovation and application of scientific instruments [2][24]. 2. Scientific Analysis Instruments - The market for scientific analysis instruments is vast, with mass spectrometers and chromatographs showing low domestic production rates. The mass spectrometer market is expected to grow significantly, with a focus on high-resolution and triple quadrupole models as key areas for domestic manufacturers to target [25][50]. 3. Electronic Measurement Instruments - The electronic measurement instruments market is rapidly expanding, with a projected market size of 16.307 billion USD globally by 2024. The domestic market is expected to exceed 40 billion yuan, with a significant portion of high-end products still being imported [4][6]. 4. Policy Guidance - Recent government policies have aimed to support the development of domestic scientific instruments, including tax exemptions for imported instruments used in research and education, which will lower costs for research institutions [21][24].

Core Viewpoint - The article highlights various high-paying job opportunities in the scientific instrument sector, emphasizing the demand for skilled professionals in sales and technical roles across different companies in China [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][20][21][22]. Job Opportunities - Shanghai Licheng Instrument Technology Co., Ltd. is seeking an international trade manager with a salary range of 12k-20k, requiring over 5 years of experience in foreign trade and team management [2]. - Jena Analytik is looking for a regional sales representative in Xi'an, offering a salary of 8k-15k, with a preference for candidates with over 3 years of sales experience in chemical analysis instruments [2]. - Shanghai Flash Spectrum Biotechnology Co., Ltd. is hiring an amino acid analyzer sales manager in Taiyuan, with a salary range of 12k-24k [3]. - Beijing Pulit Technology Instrument Co., Ltd. is recruiting a sales manager in Wuhan, offering a salary of 10k-15k, requiring 1-3 years of relevant experience [4]. - Ying Sheng Hengtai is looking for a regional sales manager in the environmental field in Tianjin, with a salary range of 8k-15k, requiring a background in related fields [5]. - Yi Lu Wu You is hiring a medical device sales representative in Wuhan, with a salary range of 5k-20k, requiring at least 2 years of relevant experience [6]. - Haineng Technology is seeking a sales engineer in Haikou, offering a salary of 8k-12k, with a preference for candidates with marketing experience in scientific instruments [7]. - Saikamu is looking for a regional sales manager in Hangzhou, with salary negotiable, open to fresh graduates [8]. - Guangzhou Hexin Instrument Co., Ltd. is hiring a sales engineer for environmental/laboratory direction in Hangzhou, with a salary range of 5k-10k [9]. - Chengbang Haoran Measurement and Control Technology is seeking a regional sales representative for centrifuges in Chengdu, with a salary range of 5k-10k [10]. After-sales Positions - Agilent Technologies (China) Co., Ltd. is hiring an after-sales engineer for laboratory project management in Nanjing, with a salary range of 13k-18k [11]. - Yuanwei Max is looking for an application engineer in multiple cities, offering a salary range of 7k-15k [12]. - Shanghai Kailai Instrument Co., Ltd. is seeking an after-sales assistant in Shanghai, with a salary range of 9k-11k [13]. - Boside Technology Co., Ltd. is hiring a technical engineer in Beijing, with a salary range of 8k-12k [14]. - Beijing Jingke Ruida Technology Co., Ltd. is looking for after-sales engineers in multiple cities, with a salary range of 6k-12k [15]. - Hunan Lingfeng Instrument Equipment Co., Ltd. is hiring after-sales engineers in Changsha, with a salary range of 6k-10k [16].

Core Viewpoint - The article highlights the contrasting trends in employee changes among 44 listed instrument companies in China for 2024, indicating a split between companies expanding their workforce and those reducing it due to revenue pressures [1][5][10]. Group 1: Overall Trends - The overall trend shows a slight increase in employee numbers among listed instrument companies, with 24 companies expanding their workforce compared to 20 companies reducing it [5][6]. - Mindray Medical leads with a total of 21,667 employees, reflecting a 20.08% increase, driven by international expansion and digital transformation [5][6]. - Nanwei Technology shows a significant employee increase of 56.60%, attributed to its acquisition of shares in Fuli Instruments and expansion in high-margin product lines [5][6]. Group 2: Employee Reductions - 20 companies experienced varying degrees of layoffs, with HeXin Instruments seeing a drastic reduction from 684 to 276 employees, a nearly 60% drop [6][10]. - Other companies with significant layoffs include Wanyi Technology, JuGuang Technology, and Blue Shield Technology, indicating a strong correlation between workforce adjustments and revenue pressures [6][10]. Group 3: R&D Investment - Mindray Medical not only leads in total employees but also has a R&D team of 5,259, accounting for nearly 25% of its workforce, with an 18.85% increase in R&D personnel [7][10]. - Nanwei Technology's R&D personnel increased by 37.14%, with R&D investment rising by 25.84%, reflecting its commitment to high-precision material development [7][10]. - Other companies like Puyuan Precision Electric and Sand Technology also reported over 10% increases in R&D personnel, indicating active investment in new technologies [7][10]. Group 4: Industry Cycle Reflection - The changes in personnel structure reflect the development stages of various sub-industries, with life science instrument companies facing downward pressure due to market demand shifts and cost-cutting policies [9][10]. - In contrast, optical instruments and environmental monitoring companies are more active, leveraging new business opportunities and technological breakthroughs [9][10]. - The ongoing competition for high-quality R&D talent is expected to intensify as companies respond to technological innovation and domestic substitution trends [10].

Investment Rating - The report maintains a positive outlook on the drone development driven by policies and recommends high-quality export chain targets in the machinery industry [2][4]. Core Insights - The report highlights the growth of the low-altitude economy, particularly through the application of drones in agriculture, which is expected to enhance the development of this sector [3][19]. - The machinery sector is anticipated to see a rebound in the second quarter, with strong resilience in both domestic sales and exports, particularly in the engineering machinery segment [3][4]. Weekly Market Review - From June 1 to June 6, 2025, the Shanghai Composite Index rose by 1.13%, while the ShenZhen Component Index increased by 1.42%, and the ChiNext Index saw a rise of 2.32%. The machinery equipment sector increased by 0.93%, outperforming the CSI 300 Index by 0.05 percentage points, ranking 19th among 31 sectors [11][13]. - Within the machinery sub-sectors, general equipment and automation equipment saw increases of 1.29% and 1.41%, respectively, while engineering machinery experienced a decline of 0.64% [11][14]. Key Sector Tracking - The low-altitude economy is supported by government initiatives, including the use of drones for agricultural surveys, which is expected to open new application areas [3][19]. - The machinery equipment sector is advised to focus on companies with strong overseas production capabilities and diversified customer bases, especially in light of expected improvements in exports to the U.S. [3][4]. Investment Recommendations - For the low-altitude economy, recommended companies include ShenChengJiao, SuJiaoKe, and WanFengAoWei among others [4]. - In the machinery equipment sector, suggested companies include Sany Heavy Industry, XCMG, and Anhui Heli for engineering machinery, and companies like Giant Star Technology and QuanFeng Holdings for the export chain [4].

Investment Rating - The report maintains a "Recommended" rating for the quantum computing industry, particularly focusing on the photonic quantum technology route [5]. Core Insights - Photonic quantum technology is one of the important routes in quantum computing, offering unique competitive advantages such as room temperature operation, long coherence times, and compatibility with existing fiber optic communication infrastructure [1][12]. - The research intensity in photonic quantum technology is high, with a gradually forming industrial ecosystem. As of September 2023, superconducting routes lead in patent applications at 51%, while photonic quantum routes account for 21% [2][16]. - Significant advancements have been made in both domestic and international research, with notable developments from companies like Xanadu and PsiQuantum, including the launch of scalable quantum computers [3][20][28]. Summary by Sections 1. Photonic Quantum as an Important Technology Route - Quantum computing, alongside quantum communication and quantum precision measurement, forms the three major fields of quantum information technology. It utilizes quantum phenomena to achieve information processing [9]. - The photonic quantum route is characterized by its ability to operate at room temperature and maintain long coherence times, making it suitable for distributed quantum computing networks [12][14]. 2. High Research Intensity and Industrial Ecosystem Formation - The photonic quantum computing industry includes four key segments: underlying support systems, photonic quantum computing prototypes, software, and application services. Major players include Xanadu and PsiQuantum [2][17]. - The development models of photonic quantum companies can be categorized into two types: full-stack development and hardware processor design [2][17]. 3. Accelerated Development of Photonic Quantum Technology - Companies like Xanadu and PsiQuantum have made significant progress in photonic quantum technology, with Xanadu planning to establish a quantum data center by 2029, deploying thousands of servers with 1 million qubits [3][20]. - In October 2023, China successfully built a 255-photon quantum computing prototype, "Jiuzhang 3," achieving a speed improvement of one million times over its predecessor [33]. 4. Investment Recommendations - The report suggests focusing on innovations in quantum computing and highlights key companies such as Guoshun Quantum and Hexin Instruments as core investment targets. It also recommends attention to quantum encryption communication companies [4][43].

Investment Rating - The report suggests a positive outlook for the scientific instruments industry, particularly in the context of domestic substitution driven by tariff uncertainties and export restrictions [4]. Core Insights - The scientific instruments market is undergoing a transformation, with domestic alternatives becoming essential due to increased import costs and supply chain risks [3][7]. - The analysis instruments market is experiencing growth, with the domestic market exceeding 30 billion yuan, and global market growth from 57.8 billion USD to 77.1 billion USD from 2017 to 2023, reflecting a CAGR of 4.92% [3][17]. - Increased R&D investment and supportive policies are expected to accelerate domestic substitution in the scientific instruments sector [3][27]. - The mass spectrometry and chromatography sectors face significant barriers, with high-end applications still dominated by foreign brands [3][4]. Summary by Sections Section 1: Domestic Substitution in Scientific Instruments - Tariff uncertainties and U.S. export controls are pushing for domestic alternatives in scientific instruments [7]. - The analysis instruments segment is a major branch of the scientific instruments industry, with high added value and a domestic market exceeding 30 billion yuan [17][11]. - R&D investment intensity is increasing, with 2024 funding reaching 3.61 trillion yuan, a growth of 8.3% year-on-year [25][26]. Section 2: Barriers in Mass Spectrometry and Chromatography - The mass spectrometry market in China reached 16.7 billion yuan in 2023, with a year-on-year growth of 19.53% [3][4]. - The chromatography market is projected to grow to around 16 billion yuan in 2024, with significant potential for domestic substitution [3][4]. Section 3: Innovation and Domestic Substitution - Companies like 聚光科技 (Juguang Technology) are turning losses into profits and expanding their business layout [4]. - 皖仪科技 (Wanyi Technology) is a leader in leak detection instruments, continuously investing in R&D [4]. - 莱伯泰科 (Leibotai Technology) is expanding from sample preparation to high-end analytical testing instruments [4]. - 雪迪龙 (Xuedilong) is actively positioning itself in the scientific instruments market, benefiting from the expansion of the carbon market [4].

Investment Rating - The report suggests a positive outlook for the scientific instruments industry, particularly in the context of domestic substitution driven by tariffs and export restrictions [4]. Core Insights - The scientific instruments market is undergoing a transformation due to increased tariffs and export controls from the U.S., pushing domestic alternatives from an option to a necessity [3][7]. - The analysis instruments market is experiencing continuous growth, with the domestic market exceeding 30 billion yuan, and the global market growing from 57.8 billion USD in 2017 to 77.1 billion USD in 2023, reflecting a CAGR of 4.92% [3][17]. - Increased R&D investment and supportive policies are expected to accelerate domestic substitution in the scientific instruments sector [3][27]. - The mass spectrometry and chromatography sectors face significant barriers, with high-end applications still dominated by foreign brands, indicating a long road ahead for domestic high-end development [3][4]. Summary by Sections Section 1: Domestic Substitution in Scientific Instruments - Tariff uncertainties and U.S. export controls are reshaping the landscape, making domestic substitution essential [3][7]. - The analysis instruments segment is a major branch of the scientific instruments industry, with high added value and a domestic market exceeding 30 billion yuan [3][17]. - R&D investment intensity is increasing, with 2024 funding reaching 3.61 trillion yuan, a growth of 8.3% year-on-year, surpassing the EU average [3][26]. Section 2: Barriers in Mass Spectrometry and Chromatography - The mass spectrometry market in China reached 16.704 billion yuan in 2023, growing by 19.53% year-on-year, but remains dominated by foreign brands [3][4]. - The chromatography market is projected to reach around 16 billion yuan in 2024, with significant potential for domestic substitution as import amounts decline [3][4]. Section 3: Innovation and R&D Focus - Companies like 聚光科技 (Juguang Technology) are turning losses into profits and diversifying their business models [4]. - 皖仪科技 (Wanyi Technology) is a leader in leak detection instruments, continuously investing in R&D [4]. - 莱伯泰科 (Leibotai Technology) is expanding from sample preparation to high-end analytical instruments, exploring new mass spectrometry technologies [4]. - 雪迪龙 (Xuedilong) is actively positioning itself in the scientific instruments market, benefiting from the expansion of the carbon market [4].

Group 1 - The core viewpoint of the articles highlights the increasing activity in the Sci-Tech Innovation Board's M&A market, driven by supportive policies, which is facilitating industrial integration and upgrading [1][2] - Recent M&A transactions include the acquisition of Aoyikex Automotive Electronics by Lingdian Electric Control, the acquisition of Sigma Microelectronics by Narui Radar, and the acquisition of Pengli Biological by Aopumai, with respective shareholder meetings scheduled for June 13, 16, and 23 [1] - According to the Shanghai Stock Exchange, after the release of the "Eight Measures for the Sci-Tech Innovation Board," there have been 105 newly disclosed M&A transactions, totaling over 33.3 billion yuan, with significant deals including Hu Silicon Industry's acquisition of minority stakes for 7.04 billion yuan and Chiplink Integration's acquisition of Chiplink Yuezhou for 5.897 billion yuan [1] Group 2 - Companies like Haiguang Information and Zhongke Shuguang are planning a share swap merger, which will enhance Haiguang's industrial layout from chips to software and systems, consolidating quality resources across the information industry chain [2] - Several companies that previously disclosed specific transaction plans are making significant progress towards achieving industrial integration, with various M&A transactions undergoing review and approval processes [2] - Notable transactions that have received approval include Chiplink Integration's acquisition of Chiplink Yuezhou and other companies like Slinjie and Huahai Chengke, which are advancing their respective M&A processes [2]

证券代码：688622 证券简称：禾信仪器 公告编号：2025-041 广州禾信仪器股份有限公司 关于 2023 年限制性股票与股票期权激励计划首次授予限制性 股票第一个归属期归属结果暨股份上市公告 广州禾信仪器股份有限公司（以下简称"公司"）近日完成了 2023 年限制性 股票与股票期权激励计划（以下简称"股权激励计划"）首次授予限制性股票第一 个归属期的股份登记工作，现将有关情况公告如下： 一、本次限制性股票归属已履行的决策程序和信息披露情况 1、2023 年 8 月 4 日，公司召开第三届董事会第十六次会议，审议通过了 《关于公司<2023 年限制性股票与股票期权激励计划（草案）> 及其摘要的议案》 《关于公司<2023 年股权激励计划实施考核管理办法>的议案》《关于提请股东大 会授权董事会办理公司股权激励相关事宜的议案》等议案。同日，公司独立董事 就本次激励计划相关议案发表了明确同意的独立意见。 2、2023 年 8 月 4 日，公司召开第三届监事会第十四次会议，审议通过了 《关于公司<2023 年限制性股票与股票期权激励计划（草案）> 及其摘要的议案》 《关于公司<2023 年股权激励计划实施考核管 ...

Core Viewpoint - The article discusses the recent changes in the management and board of directors of Guangzhou Hexin Instrument Co., Ltd., including the election of a new chairman and the appointment of senior management personnel, amidst ongoing financial challenges faced by the company [1][2]. Board of Directors Election - On May 22, 2025, the company held its first meeting of the fourth board of directors, where it unanimously elected Mr. Zhou Zhen as the chairman of the board, with his term lasting until the end of the current board's term [4]. Special Committee Elections - During the same meeting, the company elected members and conveners for its special committees, including: - Audit Committee: Chaired by Chen Ming, with members Chen Ming, Zhou Zhen, and Liu Qiliang - Nomination Committee: Chaired by Liu Qiliang, with members Liu Qiliang, Kong Yunfei, and Zhou Zhen - Compensation and Assessment Committee: Chaired by Liu Qiliang, with members Liu Qiliang, Kong Yunfei, and Zhou Zhen - Strategic Development Committee: Chaired by Zhou Zhen, with members Zhou Zhen, Xu Xiangdong, and Liu Qiliang [6]. Senior Management Appointments - The board also approved the appointment of new senior management personnel: - Xu Xiangdong as General Manager - Sun Jiande as Chief Financial Officer - Lu Wanli as Secretary of the Board These appointments are effective from the date of the board's approval until the end of the current board's term [9]. Management Changes - The company has experienced multiple changes in its executive team since 2024, including the departure of several key executives, which may indicate instability within the management structure [11][20]. Financial Performance - In 2024, the company reported a significant decline in revenue, with total revenue of 203 million yuan, a decrease of 44.70% year-on-year. The net profit attributable to shareholders was a loss of approximately 46 million yuan, marking three consecutive years of losses, with total losses exceeding 200 million yuan [21][22]. - The company's R&D expenses also saw a substantial reduction of 51.44%, with R&D investment amounting to approximately 33 million yuan, representing only 16.20% of total revenue [22][23].